Overview of the 2006 food and drug administration circulatory system devices panel meeting on drug-eluting stent thrombosis

Catheterization and Cardiovascular Interventions

Volumn 69, Issue 7, 2007, Pages 1064-1074

  Slottow, Tina L Pinto ^a   Waksman, Ron ^a,b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Drug eluting stent; Percutaneous coronary intervention; Stent thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

BLEEDING; CONSENSUS; CONTROLLED STUDY; DRUG ELUTING STENT; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; INCIDENCE; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVIEW; ST SEGMENT; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOMEDICAL RESEARCH; CARDIOVASCULAR AGENTS; DEVICE APPROVAL; HUMANS; PRACTICE GUIDELINES; PROSTHESIS DESIGN; STENTS; THROMBOSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34250163240     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21179     Document Type: Review

References (64)

1. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-706.
2. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-1124.
3. Fischman DL, Leon MB, Baim DS, et al. Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
4. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1671.
5. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Gaglione A, Goldberg SL, Tobis JM. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-1688.
6. Tolleson TR, Newby LK, Harrington RA, et al. Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol 2003;92:330-333.
7. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-1436.
8. Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, Bakhai A, Cohen DJ, Kuntz RE, Ho KK. Beyond restenosis: Five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004;110:1226-1230.
9. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
10. Hill RA, Dundar Y, Bakhai A, Dickson R, Walley T. Drug-eluting stents: An early systematic review to inform policy. Eur Heart J 2004;25:902-919.
11. December 7, 2006. Cordis Corporation Announces Clinical and Educational Programs for the CYPHER® Sirolimus-eluting Coronary Stent. Available from http://www.cordis.com/active/crdus/ en_US/html/cordis/downloads/press/ 155_5130_1_FDA_Panel_PR. pdf. p Retrieved December 12, 2006.
12. January 19, 2005. Boston Scientific Announces Implantation of Millionth TAXUS® Express2™ Coronary Stent System. Available from http://bostonscientific.mediaroom.com/index.php?s=press_ releases&item=451. p Retrieved December 12, 2006.
13. Farb A, Uchida T, Duggirala HJ. FDA Summary, Vol. 2007. FDA Circulatory System Devices Panel Meeting, December 7-8. 2006, Gaithersburg, MD. Available at http://www.fda.gov/ohrms/ dockets/ac/06/slides/2006-4253oph1_17_FDA%20Summary. pdf.
14. Camenzind E. Safety of Drug Eluting Stents: A Meta-analysis of First Generation DES programs. In: World Congress of Cardiology 2006, Barcelona, Spain, September 2006.
15. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: A meta-analysis. Eur Heart J 2006;27: 2784-2814.
16. Hayashi T, Kimura A, Ishikawa K. Acute myocardial infarction caused by thrombotic occlusion at a stent site two years after conventional stent implantation. Heart 2004;90:e26.
17. Henderson D, Gunalingam B. Very late stent thrombosis of a sirolimus-eluting stent. Cathet Cardiovasc Interv 2006;68:406-408.
18. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, Carrozza JP Jr, Chauhan MS, Rodriguez O, Kuntz RE. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-1971.
19. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-953.
20. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
21. Cutlip D. Stent Thrombosis after Drug-Eluting Stenting: Impact of a New Standard Definition on Clinical Trial Results. In: TCT 2006, October 2006, Washington DC.
22. Fiorentino RP. Stent Thrombosis: The Implications of Broader DES Use, December 7-8, 2006. Gaithersburg, MD. Available at http://www.fda.gov/ohrms/ dockets/ac/06/slides/2006-4253oph1_18_ Fiorention-FDA.pdf.
23. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxeal-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;309: 667-670.
24. Baim DS. Boston Scientific Presentation: Part II: Real-World Use of the TAXUS® Drug-Eluting Stent System, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda.gov/ohrms/ dockets/ac/06/slides/2006- 4253oph1_16_Baim-Boston%20pt2.pdf.
25. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352-356.
26. Chieffo A. Influence of Prolonged Dual Antiplatelet Use on Late Stent Thrombosis in a Large Real-World Registry: The Milan/ Siegburg/Naples Experience. In: TCT 2006, October 2006. Washington, DC.
27. Smith SC Jr. Feldman TE, Hirshfeld JW Jr. et al. ACC/AHA/ SCAI 2005 Guideline update for percutaneous coronary intervention - Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:156-175.
28. FDA Labeling. 2003. CYPHER™ Sirolimus-eluting Coronary Stent. Accessed on December 18, 2006. Availiable at http:// www.fda.gov/cdrh/PDF2/ p020026c.pdf.
29. FDA Labeling. 2003. TAXUS™ Express 2™ Paclitaxel-Eluting Coronary Stent System. Accessed on December 18, 2006. Available at http://www.fda.gov/cdrh/pdf3/P030025c.pdf.
30. Schuhlen H, Kastrati A, Mehilli J, Hausleiter J, Pache J, Dirschinger J, Schomig A. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 2004;147:317-322.
31. Assali AR, Moustapha A, Sdringola S, Denktas AE, Willerson JT, Holmes DR Jr, Smalling RW. Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial). Am J Cardiol 2006;98:729-733.
32. Nayak AK, Kawamura A, Nesto RW, Davis G, Jarbeau J, Pyne CT, Gossman DE, Piemonte TC, Riskalla N, Chauhan MS. Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J 2006;70:1026-1029.
33. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006;151:1260-1264.
34. Rogers C, Dohonoe D, Mauri L. Drug-Eluting Stent Safety Profile: Stent Thrombosis, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4253oph1_13_Rogers-Cordis. pdf.
35. Baim DS. Boston Scientific Presentation. Part I: On-label Use of the TAXUS® Drug-Eluting Stent System, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda.gov/ ohrms/dockets/ac/06/slides/2006- 4253oph1_15_Baim-Boston.pdr.
36. Cohen SA. "Real-World" Use of the CYPHER® Sirolimus-Eluting Stent: Data from Randomized Controlled Trials and Registries, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda.gov/ohnns/dockets/ac/06/ slides/2006-4253oph1_ 14_Cohen-Cordis.pdf.
37. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ, Ulm K, Schomig A. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: Meta-analysis of randomized trials. JAMA 2005;294:819-825.
38. Kuntz RE. Medtronic Vascular: Endeavor Safety Analysis, December 7-8, 2006, Gaithersburg, MD. Available at http://www. fda.gov/ohrms/dockets/ac/06/ slides/2006-4253oph2_17_Kuntz.pdf.
39. Sudhir K. Abbott Vascular Drug Eluting Stent Program, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda. gov/ohrms/dockets/ac/06/slides/ 2006-4253oph2_18_Sudhir.pdf.
40. Mauri L. Planned Combined Safety Analysis for Biolimus A9 Stents, December 7-8, 2006, Gaithersburg, MD. Available at http:// www.fda.gov/ohrms/ dockets/ac/06/slides/2006-4253oph2_19_ Mauri.pdf.
41. Michelson A. Late Stent Thrombosis After DES: Role of Platelet Function Testing, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda.gov/ ohrms/dockets/ac/06/slides/2006-4253oph1_02_Michelson.pdf.
42. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): A randomised controlled trial. Lancet 2002;360:965-970.
43. Malenka DJ, Leavitt BJ, Hearne MJ, et al. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: Analysis of BARI-like patients in northern New England. Circulation 2005:112 (Suppl 9):1371-1376.
44. Smith PK, Califf RM, Tuttle RH, Shaw LK, Lee KL, Delong ER, Lilly RE, Sketch MH Jr, Peterson ED, Jones RH. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann Thorac Surg 2006;82:1420-1428. discussion 1428-1429.
45. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP, Rose EA. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005;352:2174-2183.
46. Guyton RA. History of Evidence Based Coronary Revascularization-Can we identify our mistakes and not repeat them?, December 7-8, 2006, Gaithersburg, MD. Available at http:// www.fda.gov/ohrms/dockets/ac/06/slides/2006- 4253oph2_12_ Guyton.pdf.
47. Ferguson TB. Summary Recommendations to FDA: Society of Thoracic Surgeons' Perspective, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda.gov/ohrms/dockets/ac/06/ slides/2006-4253oph2_13_Ferguson.pdf.
48. Smith PK. Relative Merits and Clinical Selection of CABG, Bare Metal Stents, and Drug Eluting Stents in Practice and in Evolution, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda.gov/ohrms/dockets/ac/06/ slides/2006-4253oph2_ 11_Smith.pdf.
49. Dove JT. American College of Cardiology Testimony, December 7-8, 2006, Gaithersburg, MD. Available at http://www. fda.gov/ohrms/dockets/ac/06/slides/ 2006-4253oph2_20_Dove.pdf.
50. Dehmer GJ. The Society for Cardiovascular Angiography and Interventions Public Statement to the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee, December 7-8, 2006, Gaithersburg, MD. Available at http://www. fda.gov/ohrms/dockets/ac/06/slides/2006-4253oph2_21_Dehmer.pdf.
51. Smith S. The American Heart Association Public Statement to the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee. In: FDA Circulatory System Devices Panel Meeting, December 7-8, 2006, Gaithersburg, MD.
52. Wallentin L, Lagerqvist B. Long-term outcome of DES vs BMS implanted in Sweden 2003-2004, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda.gov/ohrms/dockets/ac/06/ slides/2006-4253oph1_07_Wallentin.pdf.
53. Mishkel GJ. Prairie "Real World" Drug Eluting Stent Database, December 7-8, 2006, Gaithersburg, MD. Available at http://www. fda.gov/ohrms/dockets/ac/06/slides/2006-4253oph2_06_Mishkel.pdf.
54. Magid D. Longitudinal Outcomes Following Drug Eluting Stent Implantation, December 7-8, 2006. Gaithersburg, MD. Available at http://www.fda.gov/ohrms/ dockets/ac/06/slides/2006-4253oph2_04_ Magid.pdf.
55. Williams DO. Comparisons of Drug-Eluting to Bare Metal Stents: Findings from the NHLBI-Dynamic and the DEScover Registries, December 7-8, 2006, Gaithersburg, MD. Available at http://www. fda.gov/ohrms/dockets/ac/06/slides/ 2006-4253oph2_05_Williams. pdf.
56. Williams DO, Abbott JD, Kip KE. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: Report of the DEScover registry. Circulation 2006;114:2154-2162.
57. Waksman R. DES Thrombosis: Results from Contemporary Registries at the Washington Hospital Center, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda.gov/ohrms/ dockets/ac/06/slides/2006-4253oph2_08_Waksman.pdf.
58. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168.
59. Kong DF. Drug-Eluting vs. Bare Metal Stents: Results from a Practice-Based Registry, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda.gov/ohrms/dockets/ac/06/slides/ 2006-4253oph2_03_Kong.pdf.
60. Mehran R. A Prospective "All Comers" Single Arm Study in Complex Patients: The MATRIX Trial, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda.gov/ohrms/ dockets/ac/06/slides/2006- 4253oph2_02_Mehran.pdf.
61. Kimura T, Mitsudou K, Nobuyoshi M. Preliminary One-Year Outcome After Sirolimus-Eluting Stent Implantation: The j-Cypher Registry Update, December 7-8, 2006, Gaithersburg, MD. Available at http://www.fda.gov/ohrms/dockets/ac/ 06/slides/ 2006-4253oph1_10_Kimura.pdf.
62. Browning JA, Burke N, Menssen KM, Newell MC, Mooney MR, Lips DL, Vazquez-Benitez G, Duval S, Henry TD. Impact of DES in STEMI: The Minneapolis Heart Institute Level 1 MI Program, December 7-8, 2006, Gaithersburg, MD. Available at http://www. fda.gov/ohrms/dockets/ac/06/slides/2006-4253oph2_ 14_Henry.pdf.
63. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
64. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.